No quarterly revenue total was found in LianBio's SEC filings.
LianBio (LIANY) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$16.0 million. As of Sep 30, 2023 it held $252.2 million in cash and investments and $2.8 million in total debt.
Revenue
—
Net income
$-24.04M
-9.8% vs year-ago quarter
Operating cash flow
$-15.86M
+0.6% vs year-ago quarter
Free cash flow
$-16.02M
+5.2% vs year-ago quarter
EPS
$-0.22
-10.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
108.06M
-0.3% vs year-ago quarter
Net cash
$249.38M
Q3 FY2023
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LIANY (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Princeton, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1831283
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2023 Sep 30, 2023 |
Q2 FY2023 Jun 30, 2023 |
Q1 FY2023 Mar 31, 2023 |
Q4 FY2022 Dec 31, 2022 |
Q3 FY2022 Sep 30, 2022 |
|---|---|---|---|---|---|
| Operating income | -$26.3M | -$25.0M | -$26.0M | -$29.2M | -$24.5M |
| Net income | -$24.0M | -$21.6M | -$24.0M | -$18.3M | -$21.9M |
| Diluted EPS | -$0.22 | -$0.20 | -$0.22 | -$0.17 | -$0.20 |
| Operating cash flow | -$15.9M | -$19.3M | -$17.6M | -$30.7M | -$16.0M |
| Free cash flow | -$16.0M | -$19.4M | -$17.7M | -$30.9M | -$16.9M |
| Total assets | $262.9M | $278.8M | $302.6M | $320.0M | $351.8M |
| Total liabilities | $26.8M | $23.3M | $28.2M | $26.3M | $45.2M |
| Stockholders' equity | $202.3M | $221.7M | $240.7M | $259.9M | $272.8M |
| Cash and investments | $252.2M | $267.3M | $286.5M | $302.4M | $311.7M |
| Total debt | $2.8M | $3.3M | $3.9M | $4.3M | $4.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Exit or restructuring costs, Listing notice, Regulation FD disclosure, Other events
|
Feb 13, 2024 | Feb 9, 2024 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Dec 26, 2023 | Dec 22, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 20, 2023 | Dec 19, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 19, 2023 | Dec 16, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 6, 2023 | Dec 6, 2023 |
| 8-K |
Current report
Other events
|
Dec 1, 2023 | Nov 30, 2023 |
Source: SEC EDGAR filings. This is company-reported data, not investment advice.